Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
A1LN34.SA
HoldAlnylam Pharmaceuticals, Inc. · Healthcare · United States · $31.4B · Avg Vol: $20K/d
43
StockRankGet insider-trade alerts
Q
79
V
28
M
28
P/E (TTM)
40.5x
ROE
96.6%
D/E
2.2x
Dividend %
—
COMPANY DESCRIPTION
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
FINANCIAL SUMMARY (BRL)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.4B | 9.5B | 11.7B | 19.3B | 53.0% | 25.0B | 28.6B | 36.1B | 36.7% |
| EPS (BRL) | -0.11 | -0.04 | -0.03 | 0.03 | — | — | — | — | — |
| Shares | 2.7B | 2.7B | 2.7B | 2.7B | 0.0% | 2.7B | — | — | — |
| Debt | 6.9B | 6.8B | 6.7B | 6.7B | -1.1% | 15.6B | — | — | — |
| Equity | -823.6M | -1.1B | 349.2M | 4.1B | 1076.3% | — | — | — | — |
| Op CF | -2.8B | 542.2M | -43.3M | 2.7B | 124.3% | 4.7B | — | — | — |
| Inv CF | 881.6M | -1.8B | -608.2M | 2.3B | — | — | — | — | — |
| Fin CF | 2.2B | 896.0M | 1.5B | -1.6B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-12.5%
SMA 50SMA 200
Close
$11.96
RSI (14)
79.8
52W High
$25.44
From 52W High
0.5%
SCORE BREAKDOWN
Quality
79
ROIC
32.1%97.0
ROE
96.6%98.9
GP/Assets
77.1%95.2
Op. Margin
17.9%79.0
FCF/Assets
16.5%94.4
Piotroski
784.0
Int. Cover
3.5x48.5
D/E Ratio
2.21x5.2
Current Ratio
3.06x55.2
Value
28
P/E (TTM)
40.5x25.1
EV/EBITDA
29.7x19.8
P/FCF
38.3x35.4
P/B
4.5x32.0
P/S
6.5x35.8
Div Yield
—N/A
Momentum
28
52W High %
47%19.6
RS 6M
-19%42.9
SMA 50/200
0.79x16.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$31.4B
P/E (Forward)
—
Gross Margin
79.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of A1LN34.SA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| A1LN34.SA | Alnylam Pharmaceuticals, Inc.(you) | $31.4B | 43 | Hold |
| MRNA.MX | Moderna, Inc. | $54.9B | 43 | Hold |
| RPRX | Royalty Pharma plc | $35.2B | 63 | Hold |
| APGE | Apogee Therapeutics, Inc. | $10.2B | 36 | Hold |
| RVMD | Revolution Medicines, Inc. | $44.6B | 18 | Strong Sell |
| INSM | Insmed Incorporated | $25.9B | 15 | Strong Sell |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.3B | 29 | Sell |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.4B | 39 | Hold |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.0B | 28 | Sell |
| BMRN | BioMarin Pharmaceutical Inc. | $12.5B | 60 | Hold |
Peer medians: ROE -25.1% · P/E 29.5x · Gross margin 58.8%